# Pizarra — PT-pseudo_4d54f04e26ae (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4d54f04e26ae
Task: 1

Encounter: Urology - outpatient on 17 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 34.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.352 ng/mL²
  - PSA velocity: 0.68 ng/mL/yr
  - Prior PSA: 29.7 ng/mL
  - Prostate volume: 99.5 mL
  - Months since last PSA: 1
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.739 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 34.7 ng/mL. PI-RADS 4. PSAD 0.35. Prostate volume 100 mL. DRE nodus. csPCa 0.74.

Vitals: weight 69 kg, height 174 cm, BMI 22.8, BP 108/83 mmHg, HR 67 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2007).

Chief complaint: Sustained PSA elevation alongside a Negative prior biopsy defines the current clinical presentation.

History: A sixty-six-year-old ICT consultant, never married but residing with his partner, first entered clinical evaluation in early 2023 due to an incidental PSA spike. Chronic mild lower urinary tract complaints persist, currently registering a 4 on the IPSS scale, while osteoarthritis is managed solely with paracetamol on an as-needed basis. Tobacco use ceased in 2007 following a cumulative 13 pack-year exposure; leisure activities now feature weekend hiking alongside his partner, accompanied by moderate alcohol intake averaging three units per week. Recent outpatient assessments covered routine thyroid function screening and an ophthalmology consultation for early cataract development, both demonstrating stability. Geographic distance places his residence over ninety minutes from the medical center, prompting a specific preference for remote telephone consultations during subsequent care phases.

Physical examination: DRE — prostate texture: asymmetrically hypertrophied with a distinct, firm nodule localized to the right mid-gland. General assessment remains within normal limits, displaying unremarkable cardiopulmonary findings and stable resting vital parameters.

Patient info: ICT consultant; Never married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 3 units / week; exercise Hiking on weekends; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.48 +/- 0.18   (95% CI 0.12-0.83)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

No frozen image embeddings are on file for this patient, so the image-embedding head could not be run. This contributes NO evidence in either direction — do not read the absence of a score as reassurance.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to change the decision regarding biopsy?
  - previous_notes (get_previous_notes) -> What was the prior management plan and what was agreed with the patient regarding the negative biopsy?

This case hinges on the PI-RADS score from the MRI and the management context following the prior negative biopsy, as the protocol suggests re-biopsy for PI-RADS 4-5 lesions.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, missing crucial context such as the specific PI-RADS 4 score, the PSA velocity (0.68 ng/mL/yr), and the specific context of the prior negative biopsy in relation to the guideline's risk stratification matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.48 +/- 0.18). This suggestion could be wrong because the guideline criterion explicitly mandates biopsy when the mpMRI shows a PI-RADS 4-5 lesion, which this patient has (PI-RADS 4). Furthermore, the prior failed to account for the track record where the criterion matched the reading urologist in 16 of 18 cases.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Is the PSA trend significant enough to change the decision regarding biopsy?
previous_notes - What was the prior management plan and what was agreed with the patient regarding the negative biopsy?
laboratory panel - What is the PSA density (PSA-D) value, as this is a key predictor in risk-adapted matrix tables.

GUIDELINE ANCHOR
The guideline states that a repeat biopsy is indicated when the mpMRI shows a PI-RADS 4-5 lesion, and the track record supports this criterion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radiology Division, UMCG Groningen – 10 February 2025 | Modality: Prostate mpMRI
The report identifies a PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 14 x 11 x 10 mm, with PSAD 0.352 ng/mL/mL, and a csPCa predicted probability of 0.739.

get_psa_trend
The PSA trend shows a significant rise from 29.7 ng/mL (Feb 2024) to 34.7 ng/mL (Feb 2025), indicating a rising trajectory.

get_previous_notes
The previous notes document a negative systematic sampling conducted earlier this year, and a subsequent referral for comprehensive evaluation due to sustained elevation. The management context involved a decision to evaluate forthcoming MRI findings.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI shows a PI-RADS 4 lesion in the right mid-gland peripheral zone.
- PSA trend shows a significant rise from 29.7 ng/mL to 34.7 ng/mL.
- Previous notes confirm a prior negative biopsy and a context of sustained PSA elevation.

AGAINST sampling this patient now:
- No documented ISUP grade or Gleason score for a prior cancer was found.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the PI-RADS 4 finding and the rising PSA trend, aligning with the EXPERT-PROTOCOL criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=yes, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 2}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence strongly supports proceeding with a targeted biopsy based on the PI-RADS 4 finding and rising PSA trend, aligning with the EXPERT-PROTOCOL criterion. The laboratory panel was not retrieved but did not prevent a decision.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, missing crucial context such as the specific PI-RADS 4 score, the PSA velocity (0.68 ng/mL/yr), and the specific context of the prior negative biopsy in relation to the guideline's risk stratification matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY (p=0.48 +/- 0.18). This suggestion could be wrong because the guideline criterion explicitly mandates biopsy when the mpMRI shows a PI-RADS 4-5 lesion, which this patient has (PI-RADS 4). Furthermore, the prior failed to account for the track record where the criterion matched the reading urologist in 16 of 18 cases.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Is the PSA trend significant enough to change the decision regarding biopsy?
previous_notes - What was the prior management plan and what was agreed with the patient regarding the negative biopsy?
laboratory panel - What is the PSA density (PSA-D) value, as this is a key predictor in risk-adapted matrix tables.

GUIDELINE ANCHOR
The guideline states that a repeat biopsy is indicated when the mpMRI shows a PI-RADS 4-5 lesion, and the track record supports this criterion.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_lab_results
Laboratory results show PSA at 34.7 ng/mL on 22 Jan 2025, with %Free PSA at 23%.
get_previous_notes
Previous notes document a negative systematic sampling conducted earlier this year and a subsequent referral for comprehensive evaluation due to sustained elevation. Management involved evaluating forthcoming MRI findings.

NOT RETRIEVED
get_mri_report
The full mpMRI report was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- Laboratory results show PSA at 34.7 ng/mL.
- Previous notes confirm a prior negative biopsy and a context of sustained PSA elevation.
- The PI-RADS score of 4 was noted in the initial structured panel.

AGAINST sampling this patient now:
- No documented ISUP grade or Gleason score for a prior cancer was found.

WHERE THIS LEANS
The evidence strongly supports proceeding with a targeted biopsy due to the PI-RADS 4 finding and the rising PSA trend, aligning with the EXPERT-PROTOCOL criterion.
LEAN: biopsy

[Opened in this round: laboratory_results, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=yes, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 2}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The agenda was fulfilled, leading to a consensus leaning towards biopsy based on the PI-RADS 4 finding and PSA trend. The remaining uncertainty is the lack of prior cancer pathology details.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision leans towards biopsy because the EXPERT-PROTOCOL criterion mandates re-biopsy for a PI-RADS 4-5 lesion, which was confirmed by the retrieved radiology report showing a PI-RADS 4 lesion. This finding overturned the EXPERT-PRIOR's suggestion of no biopsy by aligning with the guideline track record. The rising PSA trend further supported this conclusion, leading to a borderline consensus favoring biopsy.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
